ENHANCING THE ANTI-TUMOR IMMUNITY AND THERAPEUTIC POTENTIAL OF ICT01, A BUTYROPHILIN3A-TARGETED, gamma 9 delta 2 T CELL-ACTIVATING MONOCLONAL ANTIBODY, WITH LOW DOSE IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS: THE EVICTION-2 TRIAL
Johann de Bono
(1)
,
Stephane Champiat
(2)
,
Francois-Xavier Danlos
(2)
,
Martin Wermke
(3)
,
Volker Kunzmann
(4)
,
Aude De Gassart
,
Emmanuel Valentin
(5)
,
Marina Iche
,
Maelle Mairesse
,
Patrick Brune
(5)
,
Daniel Olive
(6, 7)
,
Paul Frohna
(5)
1
Centre for Molecular Oncology & Imaging, Institute of Cancer, Barts and The London School of Medicine and Dentistry
2 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
3 University Hospital Carl Gustav Carus [Dresden, Germany]
4 University Hospital of Würzburg
5 ImCheck Therapeutics [Marseille]
6 IPC - Institut Paoli-Calmettes
7 CRCM - Centre de Recherche en Cancérologie de Marseille
2 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
3 University Hospital Carl Gustav Carus [Dresden, Germany]
4 University Hospital of Würzburg
5 ImCheck Therapeutics [Marseille]
6 IPC - Institut Paoli-Calmettes
7 CRCM - Centre de Recherche en Cancérologie de Marseille